Acarbose improves fibrinolytic activity in patients with impaired glucose tolerance

Metabolism: Clinical and Experimental

Volumn 55, Issue 7, 2006, Pages 935-939

  Shinoda, Yuichi ^a   Inoue, Ikuo ^a   Nakano, Takanari ^a   Seo, Makoto ^a   Sassa, Masatoshi ^a   Goto, Sei ichi ^a   Awata, Takuya ^a   Komoda, Tsugikazu ^a   Katayama, Shigehiro ^a  

^a SAITAMA MEDICAL UNIVERSITY   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

ACARBOSE; FIBRINOGEN; GLUCOSE; OXIDIZED LOW DENSITY LIPOPROTEIN; PLASMINOGEN ACTIVATOR INHIBITOR 1;

ARTICLE; BLOOD CLOTTING; CARDIOVASCULAR RISK; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG EFFECT; DRUG EFFICACY; DRUG MECHANISM; FEMALE; FIBRINOGEN BLOOD LEVEL; FIBRINOLYSIS; FLATULENCE; HUMAN; HYPERGLYCEMIA; HYPERINSULINEMIA; HYPOGLYCEMIA; IMPAIRED GLUCOSE TOLERANCE; LIPOPROTEIN BLOOD LEVEL; LIVER DYSFUNCTION; MALE; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; RANDOMIZATION; RANDOMIZED CONTROLLED TRIAL; RISK REDUCTION;

ACARBOSE; BODY WEIGHT; FIBRINOGEN; FIBRINOLYSIS; GLUCOSE INTOLERANCE; HUMANS; INSULIN; LIPOPROTEINS, LDL; PLASMINOGEN ACTIVATOR INHIBITOR 1;

EID: 33745179832     PISSN: 00260495     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.metabol.2006.02.023     Document Type: Article

References (27)

1. de Marco R., Locatelli F., Zoppini G., Verlato G., Bonora E., and Muggeo M. Cause-specific mortality in type 2 diabetes. The Verona Diabetes Study. Diabetes Care 22 (1999) 756-761
2. Fuller J.H., Shipley M.J., Rose G., Jarrett R.J., and Keen H. Coronary-heart-disease risk and impaired glucose tolerance. The Whitehall study. Lancet 1 (1980) 1373-1376
3. Tominaga M., Eguchi H., Manaka H., Igarashi K., Kato T., and Sekikawa A. Impaired glucose tolerance is a risk factor for cardiovascular disease, but not impaired fasting glucose. The Funagata Diabetes Study. Diabetes Care 22 (1999) 920-924
4. Haffner S.M., Stern M.P., Mitchell B.D., Hazuda H.P., and Patterson J.K. Incidence of type II diabetes in Mexican Americans predicted by fasting insulin and glucose levels, obesity, and body-fat distribution. Diabetes 39 (1990) 283-288
5. Haffner S.M., Stern M.P., Hazuda H.P., Mitchell B.D., and Patterson J.K. Cardiovascular risk factors in confirmed prediabetic individuals. Does the clock for coronary heart disease start ticking before the onset of clinical diabetes?. JAMA 263 (1990) 2893-2898
6. Chiasson J.L., Josse R.G., Gomis R., Hanefeld M., Karasik A., and Laakso M. Acarbose treatment and the risk of cardiovascular disease and hypertension in patients with impaired glucose tolerance: the STOP-NIDDM trial. JAMA 290 (2003) 486-494
7. Bischoff H. The mechanism of alpha-glucosidase inhibition in the management of diabetes. Clin Invest Med 18 (1995) 303-311
8. Chiasson J.L., Josse R.G., Leiter L.A., Mihic M., Nathan D.M., Palmason C., et al. The effect of acarbose on insulin sensitivity in subjects with impaired glucose tolerance. Diabetes Care 19 (1996) 1190-1193
9. Chiasson J.L., Josse R.G., Gomis R., Hanefeld M., Karasik A., and Laakso M. Acarbose for prevention of type 2 diabetes mellitus: the STOP-NIDDM randomised trial. Lancet 359 (2002) 2072-2077
10. World Health Organization. Definition, diagnosis, and classification of diabetes mellitus and its complications: report of a WHO Consultation. Part I: diagnosis and classification of diabetes mellitus (1999), World Health Organization, Geneva (Switzerland)
11. Laube H., Linn T., and Heyen P. The effect of acarbose on insulin sensitivity and proinsulin in overweight subjects with impaired glucose tolerance. Exp Clin Endocrinol Diabetes 106 (1998) 231-233
12. Watanabe Y., Horie H., Hata K., Ono T., Tomono S., and Kawazu S. A new radioimmunoassay of human proinsulin. Pept Horm Pancreas 13 (1993) 69-73 [in Japanese]
13. Inoue I., Shinoda Y., Nakano T., Sassa M., Goto S., Awata T., et al. Acarbose ameliorates atherogenecity of low-density lipoprotein in patients with impaired glucose tolerance. Metabolism 55 (2006) 946-952
14. Meneilly G.S., Ryan E.A., Radziuk J., Lau D.C., Yale J.F., Morais J., et al. Effect of acarbose on insulin sensitivity in elderly patients with diabetes. Diabetes Care 23 (2000) 1162-1167
15. Rossetti L., Giaccari A., and DeFronzo R.A. Glucose toxicity. Diabetes Care 13 (1990) 610-630
16. Chiasson J.L. The effect of acarbose on insulin sensitivity in subjects with impaired glucose tolerance. Diabet Med 13 (1996) S23-S24
17. Qualmann C., Nauck M.A., Holst J.J., Ørskov C., and Creutzfeldt W. Glucagon-like peptide 1 (7-36 amide) secretion in response to luminal sucrose from the upper and lower gut. A study using alpha-glucosidase inhibition (acarbose). Scand J Gastroenterol 30 (1995) 892-896
18. Festa A., D'Agostino Jr. R., Mykkänen L., Tracy R.P., Zaccaro D.J., and Hales C.N. Relative contribution of insulin and its precursors to fibrinogen and PAI-1 in a large population with different states of glucose tolerance. The Insulin Resistance Atherosclerosis Study (IRAS). Arterioscler Thromb Vasc Biol 19 (1999) 562-568
19. Chu N.V., Kong A.P., Kim D.D., Armstrong D., Baxi S., Deutsch R., et al. Differential effects of metformin and troglitazone on cardiovascular risk factors in patients with type 2 diabetes. Diabetes Care 25 (2002) 542-549
20. Mavri A., Stegnar M., Krebs M., Sentocnik J.T., Geiger M., and Binder B.R. Impact of adipose tissue on plasma plasminogen activator inhibitor-1 in dieting obese women. Arterioscler Thromb Vasc Biol 19 (1999) 1582-1587
21. Hämäläinen H., Rönnemaa T., Virtanen A., Lindstrom J., Eriksson J.G., Valle T.T., et al. Improved fibrinolysis by an intensive lifestyle intervention in subjects with impaired glucose tolerance. The Finnish Diabetes Prevention Study. Diabetologia (2005)
22. Marckmann P., Toubro S., and Astrup A. Sustained improvement in blood lipids, coagulation, and fibrinolysis after major weight loss in obese subjects. Eur J Clin Nutr 52 (1998) 329-333
23. Song C.Y., Kim B.C., Hong H.K., and Lee H.S. Oxidized LDL activates PAI-1 transcription through autocrine activation of TGF-β signaling in mesangial cells. Kidney Int 67 (2005) 1743-1752
24. Hennig B., Toborek M., and McClain C.J. High-energy diets, fatty acids and endothelial cell function: implications for atherosclerosis. J Am Coll Nutr 20 (2001) 97-105
25. Festa A., Hanley A.J., Tracy R.P., D'Agostino Jr. R., and Haffner S.M. Inflammation in the prediabetic state is related to increased insulin resistance rather than decreased insulin secretion. Circulation 108 (2003) 1822-1830
26. Rebolledo O.R., and Actis Dato S.M. Postprandial hyperglycemia and hyperlipidemia-generated glycoxidative stress: its contribution to the pathogenesis of diabetes complications. Eur Rev Med Pharmacol Sci 9 (2005) 191-208
27. Shankar S.S., and Steinberg H.O. FFAs: do they play a role in vascular disease in the insulin resistance syndrome?. Curr Diab Rep 5 (2005) 30-35